Supplementary Figure 9 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Alykhan S. Nagji,Sang-Hoon Cho,Yuan Liu,Jae K. Lee,David R. Jones

DOI: https://doi.org/10.1158/1535-7163.22485041.v1

2023-01-01

Abstract:Supplementary Figure 9 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

What problem does this paper attempt to address?

Supplementary Figure 1 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Alykhan S. Nagji,Sang-Hoon Cho,Yuan Liu,Jae K. Lee,David R. Jones

DOI: https://doi.org/10.1158/1535-7163.22485065.v1

2023-01-01

Abstract:Supplementary Figure 1 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Figure 7 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Alykhan S. Nagji,Sang-Hoon Cho,Yuan Liu,Jae K. Lee,David R. Jones

DOI: https://doi.org/10.1158/1535-7163.22485047.v1

2023-01-01

Abstract:Supplementary Figure 7 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Figure 6 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Alykhan S. Nagji,Sang-Hoon Cho,Yuan Liu,Jae K. Lee,David R. Jones

DOI: https://doi.org/10.1158/1535-7163.22485050.v1

2023-01-01

Abstract:Supplementary Figure 6 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Supplementary Figures S1-8 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Wenfeng Fang,Yuxiang Ma,Jiani C. Yin,Shaodong Hong,Huaqiang Zhou,Ao Wang,Fufeng Wang,Hua Bao,Xue Wu,Yunpeng Yang,Yan Huang,Hongyun Zhao,Yang W. Shao,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.22472766

2023-01-01

Abstract:Supplementary Figures S1-8
Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

Li Wang,Xiangling Chu,Xin Yu,Chunxia Su

DOI: https://doi.org/10.1016/j.heliyon.2024.e27801

IF: 3.776

2024-01-01

Heliyon

Abstract:Background: Immunotherapy has become the standard treatment for advanced non-small cell lung cancer (NSCLC). However, a subset of the most advanced NSCLC patients fails to respond adequately to Immune checkpoint inhibitors (ICIs). Developing new nomograms and integrating prognostic factors are crucial for improving the clinical predictability of NSCLC patients undergoing ICIs. Methods: Clinical information and genomic data of NSCLC patients undergoing ICIs were retrieved from cBioPortal. Gene alterations associated with durable clinical benefit (DCB) were compared to those linked to no durable benefit (NDB). The Kaplan-Meier plot method was employed for survival analysis, and a novel nomogram was formulated by selecting pertinent clinical variables. Results: For the NSCLC patients receiving immunotherapy, three subgroups were identified based on the treatment regimen, including anti-PD-1 monotherapy, anti-PD-1 combination with anti-CTLA -4, and first-line treatment. The mutation status of TP53, PGR, PTPRT, RELN, MUC19, LRP1B, and FAT3 was found to be associated with progression-free survival (PFS). Using the clinicopathological parameters and genomic data of the patients, we developed three novel nomograms to predict the prognosis of ICI treatment in different subgroups. Conclusion: Our study revealed that PGR, PTPRD, RELN, MUC19, LRP1B, and FAT3 mutation could serve as predictive biomarkers. Our systematic nomograms demonstrate significant potential in predicting the prognosis for NSCLC patients with sensitivity to different ICI treatment strategies.
Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke‐Da Yu,Rui Zhu,Mei Zhan,Angel Rodriguez,Wei Yang,Stephen T.C. Wong,Andreas Makris,Brian D. Lehmann,Xi Chen,Ingrid A. Mayer,Jennifer A. Pietenpol,Zhi‐Ming Shao,W. Fraser Symmans,Jenny Chang‐Claude

DOI: https://doi.org/10.1158/1078-0432.22446909

2023-01-01

Abstract:Supplementary Figure A1 PDF file 73K, Subgroup analysis of the extended validation cohort
Supplementary Figure 1 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

Fei Yang,Ximing Tang,Erick Riquelme,Carmen Behrens,Monique B. Nilsson,Uma Giri,Marileila Varella-Garcia,Lauren A. Byers,Heather Y. Lin,Jing Wang,Maria G. Raso,Luc Girard,Kevin Coombes,J. Jack Lee,Roy S. Herbst,John D. Minna,John V. Heymach,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/0008-5472.22388304

2023-01-01

Abstract:Supplementary Figure 1 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy
Supplementary Figure 1 from Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers

Xifeng Wu,Liang Wang,Yuanqing Ye,Jeremiah A. Aakre,Xia Pu,Gee-Chen Chang,Pan-Chyr Yang,Jack A. Roth,Randolph S. Marks,Scott M. Lippman,Joe Y. Chang,Charles Lu,Claude Deschamps,Wu-Chou Su,Wen-Chang Wang,Ming-Shyan Huang,David W. Chang,Yan Li,V. Shane Pankratz,John D. Minna,Waun Ki Hong,Michelle A.T. Hildebrandt,Chao Agnes Hsiung,Ping Yang

DOI: https://doi.org/10.1158/0008-5472.22394888

2023-01-01

Abstract:PDF file - 587K, Manhattan Plot.
Supplementary Figure 2 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

Tian Ma,Fabrizio Galimberti,Cherie P. Erkmen,Vincent Memoli,Fadzai Chinyengetere,Lorenzo Sempere,Jan H. Beumer,Bean N. Anyang,William Nugent,David Johnstone,Gregory J. Tsongalis,Jonathan M. Kurie,Hua Li,James DiRenzo,Yongli Guo,Sarah J. Freemantle,Konstantin H. Dragnev,Ethan Dmitrovsky

DOI: https://doi.org/10.1158/1535-7163.22499764

2023-01-01

Abstract:PDF file - 1690K, Supplemental Fig. 2: Pharmacodynamic effects of vorinostat in (A) murine ED-1 lung cancer cells and (B) human HOP62 lung cancer cells. Vorinostat dose-dependent effects were investigated by immunoblot analyses for Bcl-2 family members (Bcl-2, Mcl-1, Bax and Bim); DNA damage response proteins (γH2AX and Chk1); the epithelial-mesenchymal transition (EMT) biomarker E-cadherin; and other growth regulatory proteins (c-raf, p-Akt, Akt, p21, and acetyl-α tubulin).
Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Wenfeng Fang,Yuxiang Ma,Jiani C. Yin,Shaodong Hong,Huaqiang Zhou,Ao Wang,Fufeng Wang,Hua Bao,Xue Wu,Yunpeng Yang,Yan Huang,Hongyun Zhao,Yang W. Shao,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.22472751.v1

2023-01-01

Abstract:Copy number alterations in genes in immune-related pathways in each patient
Supplementary Figure 1 from MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients

Xia Pu,Jack A. Roth,Michelle A.T. Hildebrandt,Yuanqing Ye,Hua Wei,John D. Minna,Scott M. Lippman,Xifeng Wu

DOI: https://doi.org/10.1158/0008-5472.22399998.v1

2023-01-01

Abstract:Supplementary Figure 1 PDF file - 122K, Supplementary figure 1 displays the histogram of p-value in bootstrap analysis
Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Marina Parry,Matthew J.J. Rose-Zerilli,Viktor Ljungström,Jane Gibson,Jun Wang,Renata Walewska,Helen Parker,Anton Parker,Zadie Davis,Anne Gardiner,Neil McIver-Brown,Christina Kalpadakis,Aliki Xochelli,Achilles Anagnostopoulos,Claudia Fazi,David Gonzalez de Castro,Claire Dearden,Guy Pratt,Richard Rosenquist,Margaret Ashton-Key,Francesco Forconi,Andrew Collins,Paolo Ghia,Estella Matutes,Gerassimos Pangalis,Kostas Stamatopoulos,David Oscier,Jonathan C. Strefford

DOI: https://doi.org/10.1158/1078-0432.22456676.v1

2023-01-01

Abstract:Supplementary Figure 2. ABSOLUTE
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Meenakshi Anurag,Eric J. Jaehnig,Karsten Krug,Jonathan T. Lei,Erik J. Bergstrom,Beom-Jun Kim,Tanmayi D. Vashist,Anh Minh Tran Huynh,Yongchao Dou,Xuxu Gou,Chen Huang,Zhiao Shi,Bo Wen,Viktoriya Korchina,Richard A. Gibbs,Donna M. Muzny,Harshavardhan Doddapaneni,Lacey E. Dobrolecki,Henry Rodriguez,Ana I. Robles,Tara Hiltke,Michael T. Lewis,Julie R. Nangia,Maryam Nemati Shafaee,Shunqiang Li,Ian S. Hagemann,Jeremy Hoog,Bora Lim,C. Kent Osborne,D.R. Mani,Michael A. Gillette,Bing Zhang,Gloria V. Echeverria,George Miles,Mothaffar F. Rimawi,Steven A. Carr,Foluso O. Ademuyiwa,Shankha Satpathy,Matthew J. Ellis

DOI: https://doi.org/10.1158/2159-8290.22541898

2023-01-01

Abstract:Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Supplementary Figure 1 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

Tian Ma,Fabrizio Galimberti,Cherie P. Erkmen,Vincent Memoli,Fadzai Chinyengetere,Lorenzo Sempere,Jan H. Beumer,Bean N. Anyang,William Nugent,David Johnstone,Gregory J. Tsongalis,Jonathan M. Kurie,Hua Li,James DiRenzo,Yongli Guo,Sarah J. Freemantle,Konstantin H. Dragnev,Ethan Dmitrovsky

DOI: https://doi.org/10.1158/1535-7163.22499770

2023-01-01

Abstract:PDF file - 652K, Supplemental Fig. 1: The structure of vorinostat (SAHA).
Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Wenfeng Fang,Yuxiang Ma,Jiani C. Yin,Shaodong Hong,Huaqiang Zhou,Ao Wang,Fufeng Wang,Hua Bao,Xue Wu,Yunpeng Yang,Yan Huang,Hongyun Zhao,Yang W. Shao,Li Zhang

DOI: https://doi.org/10.1158/1078-0432.22472763.v1

2023-01-01

Abstract:Detailed individual characteristics of each patient
Abstract PD07-09: Hypoxia (VEGF-S) Signature and CRYAB Predict Response to Neoadjuvant Anthracycline/Taxane Containing Chemotherapy Within Triple Negative and Unselected Breast Tumors

M. C. U. Cheang,J. S. Parker,X. He,W. Zhao,C. Fan,A. Prat,L. Carey,C. M. Perou

DOI: https://doi.org/10.1158/0008-5472.sabcs10-pd07-09

IF: 11.2

2010-01-01

Cancer Research

Abstract:Abstract Background: Aggressive breast tumors are a clinically challenge to manage. A VEGF-signature (VEGF-s) developed in vivo (Hu et al. BMC Med. 09) and the profile of the anti-apoptotic gene and regulator of tumor angiogenesis, CRYAB (Moyano et al. J Clin Invest 06; Dimberg et al. Blood 08), are both associated with distant metastasis. In this study, we sought to test if these two mechanistically related biomarkers predict pathological complete response(pCR) to anthracyline/taxane-based neoadjuvant chemotherapy. Methods: Gene expression data of pre-treatment fresh frozen tumors were combined, 149 from the ISPY trial (Agilent 44K) and 225 from MD Anderson Cancer Center(MDACC) (Affymetrix HG U133A). Patients from I-SPY were treated with doxorubicin/cyclophosphamide followed by a taxane. Patients from MDACC were treated with paclitaxel followed by sequential fluorouracil-AC. Tumors were classified into intrinsic subtypes using PAM50(Parker et al. J Clin Oncol 09) and Claudin-low(CL) predictor(Prat et al., Submitted). Odds ratios of biomarkers to pCR were determined using logistic regression. Predictive values of multivariable models were estimated using receiver operating characteristic curve. Results: 319 patients had complete data; the pCR rate was similar between the datasets (ISPY 22%, MDACC 20%). Both the VEGF-s and CRYAB were highly expressed within Basal-like(BL) and CL (P<0.0001); these two biomarkers were positively correlated with each other (r: 0.4, P<0.001). In univariate analysis, both VEGF-s (P<0.001) and CRYAB (P<0.001) were significantly associated with pCR. A multivariable test including tumor size, grade, ER, Her2, intrinsic subtypes, VEGF-s and CRYAB, had an AUC value of 0.86 to predict pCR(Table 1). T stage, Her2, intrinsic subtypes and CRYABwere significant. 82 patients with triple-negative tumors within this combined cohort. In univariate analysis, T stage, grade or classifying tumors into BL vs not did not predict pCR; but VEGF-s (p= 0.04) and CRYAB (p = 0.02) were associated with pCR. Multivariable model, including VEGF-s, CRYAB and the clinical variables, had a predictive value of 0.71 to pCR(Table 1), which identified CRYAB as the most significant factor by likelihood ratio test. Table 1: Multivariable logistic regression models to predict pCR. Conclusion: VEGF-s and CRYAB expression are associated with aggressive subtypes and may possibly help to predict response of anthracycline/taxane-based neoadjuvant chemotherapy beyond ER, Her2, and intrinsic subtypes. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD07-09.
Prediction Models for Platinum-Based Chemotherapy Response and Toxicity in Advanced NSCLC Patients.

Ji-Ye Yin,Xi Li,Xiang-Ping Li,Ling Xiao,Wei Zheng,Juan Chen,Chen-Xue Mao,Chao Fang,Jia-Jia Cui,Cheng-Xian Guo,Wei Zhang,Yang Gao,Chun-Fang Zhang,Zi-Hua Chen,Hui Zhou,Hong-Hao Zhou,Zhao-Qian Liu

DOI: https://doi.org/10.1016/j.canlet.2016.04.029

IF: 9.756

2016-01-01

Cancer Letters

Abstract:In this study, we aimed to establish a platinum-based chemotherapy response and toxicity prediction model in advanced non-small cell lung cancer (NSCLC) patients. 416 single nucleotide polymorphisms (SNPs) in 185 genes were genotyped, and their association with drug response and toxicity were estimated using logistic regression. Nine data mining techniques were employed to establish the prediction model; the sensitivity, specificity, overall accuracy and receiver operating characteristic (ROC) curve were used to assess the models' performance. Finally, selected models were validated in an independent cohort. The models established by naïve Bayesian algorithm had the best performance. The response prediction model achieved a sensitivity of 0.90 and a specificity of 0.47 with the ROC area under curve (AUC) of 0.80. The overall toxicity prediction model achieved a sensitivity of 0.86 and a specificity of 0.46 with the ROC AUC of 0.73. The hematological toxicity prediction model achieved a sensitivity of 0.89 and a specificity of 0.39 with the ROC AUC of 0.76. The gastrointestinal toxicity prediction model achieved a sensitivity of 0.93 and a specificity of 0.35 with the ROC AUC of 0.80. In conclusion, we provided platinum-based chemotherapy response and toxicity prediction models for advanced NSCLC patients.
Supplementary Tables 1-4 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

Fei Yang,Ximing Tang,Erick Riquelme,Carmen Behrens,Monique B. Nilsson,Uma Giri,Marileila Varella-Garcia,Lauren A. Byers,Heather Y. Lin,Jing Wang,Maria G. Raso,Luc Girard,Kevin Coombes,J. Jack Lee,Roy S. Herbst,John D. Minna,John V. Heymach,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/0008-5472.22388301

2023-01-01

Abstract:Supplementary Tables 1-4 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy
Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Renata Ferrarotto,Ruchitha Goonatilake,Suk Young Yoo,Pan Tong,Uma Giri,Shaohua Peng,John D. Minna,Luc Girard,Yuehong Wang,Liguang Wang,Lerong Li,Lixia Diao,David H. Peng,Don L. Gibbons,Bonnie S. Glisson,John V. Heymach,Jing Wang,Lauren A. Byers,Faye M. Johnson

DOI: https://doi.org/10.1158/1078-0432.22458884.v1

2023-01-01

Abstract:Supplemental Tables and Supplementary Figure Legends

Supplementary Figure 9 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Supplementary Figure 1 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Supplementary Figure 7 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Supplementary Figure 6 from Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer

Supplementary Figures S1-8 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Supplementary Figure 1 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

Supplementary Figure 1 from Genome-Wide Association Study of Genetic Predictors of Overall Survival for Non–Small Cell Lung Cancer in Never Smokers

Supplementary Figure 2 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

Table S5 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Supplementary Figure 1 from MicroRNA-Related Genetic Variants Associated with Clinical Outcomes in Early-Stage Non–Small Cell Lung Cancer Patients

Supplementary Figure 2 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Figure 1 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer

Table S1 from Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer

Abstract PD07-09: Hypoxia (VEGF-S) Signature and CRYAB Predict Response to Neoadjuvant Anthracycline/Taxane Containing Chemotherapy Within Triple Negative and Unselected Breast Tumors

Prediction Models for Platinum-Based Chemotherapy Response and Toxicity in Advanced NSCLC Patients.

Supplementary Tables 1-4 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer